Alterity Therapeutics Limited Stock News

Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disord

The stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) increased by over 20% pre-market. This is why it happened.

Alterity Therapeutics Ltd (ATHE) CEO David Stamler on Q2 2021 Results - Earnings Call Transcript

As of 1:46 PM ET, the stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) (ASX: ATH) is trading up 153.48% at $2.92 (up from the previous close of $1.15). Why is this happening?

Alterity Therapeutics (ATHE) news for Monday includes approval of a new patent protecting its drugs pushing ATHE stock higher. The post Alterity Therapeutics News: 8 Things for ATHE Stock Investors to

Shares of Alterity Therapeutics Ltd (NASDAQ: ATHE) gap-opened Monday's session higher and are sustaining the gains. What Happened: The Australian biopharma said the U.S. Patent and Trademark Office

The U.S.-listed shares of Alterity Therapeutics Ltd. rocketed 129.6% on massive volume in morning trading Monday, enough to be the biggest gainer among those listed on major U.S. exchanges, after the

MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients w

Alterity Therapeutics (NASDAQ: ATHE) shares are trading lower on Wednesday.This is a potential sell-off after the stock increased over 200% yesterday following the company announcing it will present a

Shares of Alterity Therapeutics Ltd. nearly tripled (up 173%) toward a 3-year high on heavy volume in premarket trading Tuesday, after the therapeutic drugs developer said it will present positive da

The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday.What Happened: The surge came

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) h

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 July

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) * ADC Therapeutics SA (NYSE: ADCT) * Akebia Therapeu

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the deve